[go: up one dir, main page]

EP0921805A4 - Peptide, die von melanomspezifischen a1-, a2- und a3-beschränkten zytotoxischen lymphozyten erkannt werden, sowie deren verwendungen - Google Patents

Peptide, die von melanomspezifischen a1-, a2- und a3-beschränkten zytotoxischen lymphozyten erkannt werden, sowie deren verwendungen

Info

Publication number
EP0921805A4
EP0921805A4 EP97919930A EP97919930A EP0921805A4 EP 0921805 A4 EP0921805 A4 EP 0921805A4 EP 97919930 A EP97919930 A EP 97919930A EP 97919930 A EP97919930 A EP 97919930A EP 0921805 A4 EP0921805 A4 EP 0921805A4
Authority
EP
European Patent Office
Prior art keywords
melanoma
specific cytotoxic
cytotoxic lymphocytes
peptides recognized
lymphocytes restricted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97919930A
Other languages
English (en)
French (fr)
Other versions
EP0921805A1 (de
Inventor
Craig L Slingluff
Donald F Hunt
Jeffrey Shabanowitz
Andrea L Cox
Victor H Engelhard
David Kittlesen
J Binswood Avenue Skipper
Ronald C Hendrikson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
University of Virginia UVA
Original Assignee
University of Virginia UVA
University of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia UVA, University of Virginia Patent Foundation filed Critical University of Virginia UVA
Publication of EP0921805A1 publication Critical patent/EP0921805A1/de
Publication of EP0921805A4 publication Critical patent/EP0921805A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP97919930A 1996-03-19 1997-03-17 Peptide, die von melanomspezifischen a1-, a2- und a3-beschränkten zytotoxischen lymphozyten erkannt werden, sowie deren verwendungen Withdrawn EP0921805A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27627 1979-04-06
US1397296P 1996-03-19 1996-03-19
US2762796P 1996-10-04 1996-10-04
PCT/US1997/004958 WO1997034613A1 (en) 1996-03-19 1997-03-17 Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor
US13972 2001-12-11

Publications (2)

Publication Number Publication Date
EP0921805A1 EP0921805A1 (de) 1999-06-16
EP0921805A4 true EP0921805A4 (de) 2002-06-26

Family

ID=26685490

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97919930A Withdrawn EP0921805A4 (de) 1996-03-19 1997-03-17 Peptide, die von melanomspezifischen a1-, a2- und a3-beschränkten zytotoxischen lymphozyten erkannt werden, sowie deren verwendungen

Country Status (4)

Country Link
EP (1) EP0921805A4 (de)
AU (1) AU712820B2 (de)
CA (1) CA2249390C (de)
WO (1) WO1997034613A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763071B1 (fr) * 1997-05-07 2003-05-16 Centre Nat Rech Scient Analogues peptidiques, et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic
JP2002533357A (ja) * 1998-12-24 2002-10-08 ニューヨーク メディカル カレッジ 疾病の治療に有用なペプチドミミック
EP1150708A2 (de) * 1999-02-11 2001-11-07 Genzyme Corporation Polynucleotide, welche für multimer von antigenen peptiden kodieren, zur erhöhung der präsentation des antigenen peptids durch mhc moleküle
ATE391726T1 (de) 1999-10-22 2008-04-15 Sanofi Pasteur Ltd Modifiziertes gp100 und dessen verwendung
WO2001032193A1 (en) * 1999-10-29 2001-05-10 Argonex Pharmaceuticals Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
EP1355926A2 (de) * 2000-05-31 2003-10-29 Genzyme Corporation Therapeutische verbindungen für eierstockkrebs
WO2002060390A2 (en) * 2001-01-04 2002-08-08 Yale University Induction of immune responses to isoaspartyl-modified antigens
EP2314712B1 (de) 2001-11-07 2014-01-08 Mannkind Corporation Für Epitope von Antigenen kodierende Expressionsvektoren sowie Verfahren zu deren Konzeption
DE102005041616B4 (de) * 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
EP2232258A4 (de) 2007-12-05 2011-01-05 Govt Of The U S A As Represented By The Secretary Of The Dept Of Health & Human Services Verbesserte virale proteinquantifizierung und impfstoffqualitätskontrolle damit

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4478823A (en) * 1977-09-28 1984-10-23 National Research Development Corporation Immunological preparations containing purified MHC antigens bonded to other antigens
WO1995022561A2 (en) * 1994-02-16 1995-08-24 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
WO1995025122A1 (en) * 1994-03-17 1995-09-21 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis c virus
WO1998033810A2 (en) * 1997-01-30 1998-08-06 University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by a3-restricted cytotoxic lymphocytes, and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1025849T5 (da) * 1992-12-22 2003-02-24 Ludwig Inst Cancer Res Fremgangsmåder til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-antigener

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4478823A (en) * 1977-09-28 1984-10-23 National Research Development Corporation Immunological preparations containing purified MHC antigens bonded to other antigens
WO1995022561A2 (en) * 1994-02-16 1995-08-24 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
WO1995025122A1 (en) * 1994-03-17 1995-09-21 The Scripps Research Institute Peptides for inducing cytotoxic t lymphocyte responses to hepatitis c virus
WO1998033810A2 (en) * 1997-01-30 1998-08-06 University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by a3-restricted cytotoxic lymphocytes, and uses therefor

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHINTAMANENI ET AL: "A single base insertion in the putative transmembrane domain of the tyrosinase gene as a cause for tyrosinase-negative oculocutaneous albinism", PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 5272 - 5276 *
COX ET AL: "Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines", SCIENCE, vol. 264, 1994, pages 716 - 719 *
KAST ET AL: "Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins", vol. 152, 1994, pages 3904 - 3912 *
See also references of WO9734613A1 *
TRAVERSARI ET AL: "A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E", J. EXP. MED., vol. 176, 1992, pages 1453 - 1457 *
WÖLFEL ET AL: "Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes", EUR. J. IMMUNOL., vol. 24, 1994, pages 759 - 764 *

Also Published As

Publication number Publication date
AU712820B2 (en) 1999-11-18
CA2249390C (en) 2007-12-18
AU2424397A (en) 1997-10-10
CA2249390A1 (en) 1997-09-25
WO1997034613A1 (en) 1997-09-25
EP0921805A1 (de) 1999-06-16

Similar Documents

Publication Publication Date Title
NL300127I2 (nl) Interferon conjugaten.
NO963955D0 (no) Manipuleringsikkert, barnebestandig lukke
NO981488L (no) Hydroksyklon-gasseparator
DE59703268D1 (de) Gassack
FI950715A0 (fi) Ytmikromekanisk, symmetrisk tryckskillnadsgivare
ITTO950169A0 (it) Airbag con scarico controllato.
EP0921805A4 (de) Peptide, die von melanomspezifischen a1-, a2- und a3-beschränkten zytotoxischen lymphozyten erkannt werden, sowie deren verwendungen
BR9609884A (pt) N-aril- 1,2,4-triazolin-5-onas
DE69618634D1 (de) 1,4-benzodioxin-derivate
TR199500915A2 (tr) Peptidler.
NO960499L (no) Antineurodegenerativt virksomme 10-aminoalifatyldibenz[b,fÅoksepiner
HK1001404A1 (en) Isolated, tyrosinase derived peptides and uses thereof.
NO982304D0 (no) 25-Hydroksy-16-ene-26,27-bishomo-cholecalciferoler
IT1284638B1 (it) Elettrodo a diffusione di gas.
DE59708914D1 (de) Beuteimitierendes, Stückiges Futtermittel
NO962931D0 (no) N,N-Dietyl-8,8-dipropyl-2-azaspiro[4,5Ådecan-2-propanamindimaleat
NL1005388A1 (nl) Monoverpakking.
ES1036009Y (es) Vitrina de gases perfeccionada.
ES1028821Y (es) Dispositivo de premontaje en cilindro a gas.
ES1031746Y (es) Bolsa suspendible.
ES1030777Y (es) Sobre-bolsa perfeccionado.
ES1031439Y (es) Metopa sujetabaldas.
ES1031411Y (es) Embalaje.
ES1030008Y (es) Somier abatible perfeccionado.
ES1030007Y (es) Somier abatible perfeccionado.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981019

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020515

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07K 14/705 A, 7C 07K 14/47 B, 7C 12N 15/11 B, 7A 61K 39/00 B

17Q First examination report despatched

Effective date: 20050405

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051018